Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort - Archive ouverte HAL Access content directly
Journal Articles BMC Infectious Diseases Year : 2019

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

(1, 2) , (3) , (4) , (5) , (4) , (6) , (7) , (8, 9) , (10) , (11) , (12) , (13) , (14) , (15) , (16, 17) , (18) , (19) , (20) , (21, 22) , (23) , (24) , (25) , (26) , (27) , (28) , (29) , (29) , (4) , (1, 2) , (4) , (1, 2)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Paul Calès
Ghassan Riachi
  • Function : Author

Abstract

Background: Although real-life results of sofosbuvir/simeprevir have been extensively reported from the United States, data from other geographical areas are limited. In the French observational cohort, ANRS CO22 HEPATHER, 9432 patients were given the new oral antivirals from December 2013 to June 30, 2018. We report the results of sofosbuvir/simeprevir in genotypes 1- and 4-infected patients.Methods: Demographics and history of liver disease were collected at entry in the cohort. Clinical, adverse events, and virological data were collected throughout treatment and post-treatment follow-up. The choice of treatment duration or addition of ribavirin was left up to the physician.Results: Five hundred ninety-nine HCV (467 genotype 1 and 132 genotype 4) mono-infected, naïve for all oral-DAAs regimen patients were given sofosbuvir/simeprevir with (n = 63) or without ribavirin (n = 536) for 12 or 24 weeks; 56% had cirrhosis (4% decompensated) and 71% had prior treatment failure to interferon-based regimen. 7 patients (1.16%) were lost to follow-up. The overall SVR12 rate was 92.6%. The SVR12 was 90% in GT1a, 94.2% in GT1b and 91.6% in GT4 with no significant difference for genotype, treatment duration or ribavirin addition. Severity of liver disease was not associated with a lower SVR12 rate on multivariate analysis but was associated with a higher rate of severe side effects. Early treatment discontinuations were rare; no new safety signals were reported.Conclusion: In this real life, observational, prospective cohort study, the 12-week sofosbuvir/simeprevir+/−ribavirin combination appears to be efficient and safe.
Fichier principal
Vignette du fichier
Laurin_et_al_2019_BMC_Infect_Dis.pdf (1.15 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

hal-02120879 , version 1 (23-05-2019)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Anne Laurain, Sophie Metivier, Georges Haour, Dominique Larrey, Céline Dorival, et al.. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infectious Diseases, 2019, 19 (1), pp.300. ⟨10.1186/s12879-019-3923-5⟩. ⟨hal-02120879⟩
413 View
88 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More